Sinclair Pharma PLC Ellans Approved for Sale in Brazil (9442B)
January 16 2018 - 2:00AM
UK Regulatory
TIDMSPH
RNS Number : 9442B
Sinclair Pharma PLC
16 January 2018
Ellansé(R) Approved for Sale in Brazil
Second generation collagen stimulator approved by ANVISA
Launch anticipated within weeks
London, 16 January 2018 Sinclair Pharma plc (AIM:SPH.L)
("Sinclair" or the "Group"), the international aesthetics company,
is pleased to announce that it has received regulatory approval of
Ellansé(R) by ANVISA in Brazil.
Brazil is the one of the leading aesthetic dermatology markets
with around 1.3 million* injectable procedures estimated to have
taken place in 2017.
Ellansé is the first of a new class of pre-mixed bioresorbable
collagen stimulating fillers. The 'L' and 'E' formulations are the
longest acting, non-permanent products available, and with all four
formulations ('S', 'M', 'L', 'E') approved at the outset, Sinclair
will offer Tunable Longevity(TM) providing up to 4 years clinical
benefit.
In anticipation of this approval and ahead of launch, Sinclair
had created an Ellansé Brazil Advisory Board comprising some of the
most influential plastic surgeons and dermatologists in that
market. Chaired by Dr Reinaldo Tovo and Dr Antonio Graziosi, this
group of key opinion leaders is already educating the clinician
community throughout Brazil and more widely in Latin America.
Dr Antonio Graziosi - "Ellansé is a new class of dermal fillers
that brings duration, with the benefit of collagen stimulation and
volume, to our patients. It's an amazing alternative for me and for
Brazilian clinicians."
Dr Reinaldo Tovo - "The use of fillers that can also safely
biostimulate the production of one's own collagen is a new concept
that is revolutionising treatments. This new polycaprolactone
filler can produce an effect, which lasts four years, creating
positive results for doctors and patients."
In anticipation of approval early in 2018, Sinclair invested in
multiple pre-launch activities including physician training during
H2 2017. Today's news means that the product can now be 'soft
launched' immediately, ahead of our planned full launch at the end
of Q1. A busy calendar of educational, promotional and training
events is scheduled for 2018, including our first LATAM World
Experts' Meeting in Rio de Janeiro in June. Over 1,000
dermatologists and plastic surgeons are expected to attend this two
day Sinclair only event.
Sinclair's Brazilian affiliate has already delivered very strong
sales traction for Silhouette Soft(R) and more recently
Perfectha(R). This affiliate is Sinclair's largest by revenue and
headcount, with coverage across all the major cities and a
commercial team comprising 42 sales representatives. Silhouette
Soft sales in Brazil are already the highest in any territory where
it is approved. Perfectha was brought in-house early last year, but
due to regulatory reasons could only be relaunched by Sinclair in
Q4 2017. The launch has so far been highly successful and the
product already looks set to surpass its previous market share.
Chris Spooner, CEO, commented: "This is a great start to the
year and builds on the commercial momentum from 2017. Pre-marketing
and product training activities in Brazil have already generated
widespread interest in Ellansé, aided by a new Advisory Board
comprising top plastic surgeons and dermatologists, renowned
throughout the world as well as South America. Sinclair has a very
busy programme of launch and training events including our first
LATAM 'WEM', and I am confident in our Brazilian team's ability to
rapidly convert this investment into strong sales growth. More
broadly, Ellansé in-market sales growth exceeded 30% in Q4 2017 and
aided by this approval and strong trends in several other markets,
we expect this growth rate to accelerate through 2018."
*Millenium Research
Ends
For further information please contact:
Sinclair Pharma plc Tel: +44 (0) 20 7467
6920
Chris Spooner
Alan Olby
Andy Crane
Peel Hunt LLP (NOMAD and Tel: +44 (0) 20 7418
Joint Broker) 8900
James Steel
Oliver Jackson
RBC Capital Markets (Joint Tel: +44 (0) 20 7653
Broker) 4000
Marcus Jackson
Laura White
Media enquiries
FTI Consulting Tel: +44 (0) 203 727
1000
Ben Atwell
Brett Pollard
Stephanie Cuthbert
About Ellansé(R)
Ellansé is a tailor-made bioresorbable collagen stimulator.
Ellansé works by not only correcting the wrinkles and folds in the
skin, but also by stimulating the body's own collagen for a
long-lasting, natural result. It is fully resorbed by the body over
time. Ellansé is different to other dermal fillers which are
commercially available, offering a unique combination of total and
predictable bio-resorbability for its entire range. Only
administered by trained physicians, Ellansé offers a personalised
treatment option with a sustained duration of 12 months (Ellansé-S)
up to 4 years (Ellansé-E).
See www.ellanse.com
About Sinclair Pharma plc - www.sinclairpharma.com
Sinclair Pharma plc is an international company operating in the
fast growth, high gross margin, global aesthetics market. Sinclair
has built a strong portfolio of differentiated, complementary
aesthetics technologies, which are experiencing significant growth,
targeting unmet clinical needs for effective, high quality, longer
duration, natural looking and minimally-invasive treatments.
Against the background of a dynamic market growth rate, Sinclair is
planning multiple new launches and line extensions over the next
few years, notably in China and the USA. The Group has an
established sales and marketing presence in the leading EU markets,
Brazil and South Korea, and a network of international distributors
including the US.
"Safe Harbor" Statement under the US Private Securities
Litigation Reform Act of 1995: Some or all of the statements in
this document that relate to future plans, expectations, events,
performances and the like are forward--looking statements, as
defined in the US Private Securities Litigation Reform Act of 1995.
Actual results of events could differ materially from those
described in the forward--looking statements due to a variety of
factors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
REAKELFFVFFEBBZ
(END) Dow Jones Newswires
January 16, 2018 02:00 ET (07:00 GMT)
Sinclair Pharma (LSE:SPH)
Historical Stock Chart
From Apr 2024 to May 2024
Sinclair Pharma (LSE:SPH)
Historical Stock Chart
From May 2023 to May 2024